









Markets
/
Stocks
/
nasdaq-imrx
/

Immuneering Corp

IMRX

6.660USD

+0.040+0.60%

Market hours （ET）Quotes delayed by 15 min

239.68MMarket Cap

LossP/E TTM



Immuneering Corp

6.660

+0.040+0.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immuneering Corp

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immuneering Corp's Score

Industry at a Glance

Industry Ranking

107 / 407

Overall Ranking

223 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

16.333

Target Price

+154.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immuneering Corp Highlights

StrengthsRisks

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -3.49, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 20.50M shares, increasing 32.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.06M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.58.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.79, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.79

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Immuneering Corp's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 5.98, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.49, which is -84.52% below the recent high of -0.54 and -97.52% above the recent low of -6.89.

Score

Industry at a Glance

Previous score

5.98

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Immuneering Corp is 13.50, with a high of 30.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

16.333

Target Price

+146.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Immuneering Corp

IMRX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 8.61, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 7.44 and the support level at 5.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.18

Change

1.43

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Neutral

RSI(14)

53.747

Neutral

STOCH(KDJ)(9,3,3)

58.008

Neutral

ATR(14)

0.499

High Vlolatility

CCI(14)

66.721

Neutral

Williams %R

27.604

Buy

TRIX(12,20)

-0.166

Sell

StochRSI(14)

47.817

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

6.568

Buy

MA10

6.433

Buy

MA20

6.114

Buy

MA50

6.735

Sell

MA100

5.241

Buy

MA200

3.432

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 35.55%, representing a quarter-over-quarter decrease of 4.54%. The largest institutional shareholder is The Vanguard, holding a total of 1.06M shares, representing 1.83% of shares outstanding, with 46.14% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

8.79M

+3876.04%

HBM Partners AG

3.65M

Zeskind (Benjamin J)

3.21M

+0.31%

Merrin Investors, L.L.C.

2.77M

Carpenter (Robert J)

1.15M

Feinberg (Peter)

1.13M

+1.12%

The Vanguard Group, Inc.

Star Investors

1.06M

Marshall Wace LLP

573.86K

-28.97%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.24, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.